



#### **THURSDAY, MAY 4**

**Educational Session: Genomics** 

3:00 pm-5:00 pm

Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

3:00-3:20	Molecular Tumor Board - Case Presentation Lillian L. Siu and William C. Hahn
3:20-3:55	Clinical applications: Drug access and design of genotype-specific trials Lillian L. Siu
3:55-4:30	Opportunities for translational and discovery research: "Next-Gen" genomics William C. Hahn, Dana-Farber Cancer Institute, Boston, MA
4:30-5:00	Panel Discussion / Questions from audience Lillian L. Siu and William C. Hahn

#### **Break**

5:00 pm-5:30 pm

#### **Welcome and Opening Remarks**

5:30 pm-6:00 pm

5:30-6:00 Welcome

Margaret Foti, American Association for Cancer Research, Philadelphia, PA

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

Carlos Gil M. Ferreira, D'or Institute for Research and Education, Rio de Janeiro,

Brazil

## Plenary Session 1: Immune Checkpoints: Successes and What We Have Learned

6:00 pm-7:30 pm

Session Chair: Joao P.B. Viola, Brazilian National Cancer Institute, Rio de Janiero, Brazil

6:00-6:30 Selective pressure by activated T cells identifies de novo and adaptive resistance

mechanisms in melanoma

Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA





6:30-7:00 State of clinical success of immune checkpoints (new preclinical data on anti-PD-1

and ant-PDL-1)

Cristina B. Bonorino, Pontifícia Universidade Católica do Rio Grande do Sul, Porto

Alegre, RS, Brazil

7:00-7:30 ER stress responses as new immune checkpoints in cancer

Juan R. Cubillos-Ruiz, Weill Cornell Medical College, New York, NY

## **Opening Reception**

7:45 pm-9:30 pm

#### FRIDAY, MAY 5

#### **Keynote Lecture 1**

8:30 am-9:15 am

Session Chair: Carlos Gil M. Ferreira, D'or Institute for Research and Education, Rio de Janeiro, Brazil

8:30-9:15 The different facets of cervical cancer prevention

Luisa L. Villa, Fundação Faculdade de Medicina de S Paulo, São Paulo, SP, Brazil

## **Break**

9:15 am-9:45 am

#### **Plenary Session 2: Tumor Heterogeneity**

9:45 am-10:45 am

Session Chair: Felipe C. Geyer, Memorial Sloan Kettering Cancer Center, New York, NY

9:45-10:15 The dynamics of cancer cell heterogeneity

Guido Lenz, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

10:15-10:45 Intra-tumour genetic heterogeneity

Felipe C. Geyer

#### **Break**

10:45 am-11:00 am





# **Plenary Session 3: Hematologic Malignancies**

11:00 am-12:30 pm

Session Chair: Eliana Abdelhay, Brazilian National Cancer Institute, Rio de Janiero, Brazil

11:00-11:30	Epigenetic mechanisms in pathogenesis and targeted therapy for B-cell lymphomas Ari M. Melnick, Weill Cornell Medical College, New York, NY
11:30-12:00	Clinical networking as a tool to improvement of leukemia care and research in developing countries: The experience of the International Consortium on Acute Leukemias (ICAL) Eduardo Magalhães Rego, University of São Paulo, Sao Paulo, Brazil
12:00-12:30	Novel therapeutic targets in multiple myeloma Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA

## Poster Session A / Lunch

12:30 pm-3:00 pm

# Plenary Session 4: Precision Medicine / Targeted and Combination Therapies / Drug Resistance 3:15 pm-4:45 pm

Session Chair: Oscar G. Arrieta, Instituto Nacional de Cancerología, Mexico City, Mexico

3:15-3:45	A systems approach to rational combination therapy with PARP inhibitors Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX
3:45-4:15	Evolution and clinical impact of co-occurring genetic alterations in lung cancer Trever G. Bivona, University of California, San Francisco, CA
4:15-4:45	Overcoming drug resistance and tumor heterogeneity in gastrointestinal cancers Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, MA

#### **Break**

4:45 pm-5:00 pm

## Plenary Session 5: Liquid Biopsies/Organoids/PDX

5:00 pm-6:30 pm

Session Chair: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

5:00-5:30 *Circulating tumor DNA is a "liquid biopsy" for precision medicine: Basic concepts*Anamaria A. Camargo, Ludwig Institute for Research on Cancer, Sao Paulo, Brazil



5:30-6:00	Patient-derived xenografts and organoids to predict therapeutic response for breast cancer patients  Alana L. Welm, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
6:00-6:30	Title to be announced Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA

# **SATURDAY, MAY 6**

## **Keynote Lecture 2**

8:30 am-9:15 am

Session Chair: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

Defining a cancer dependencies map William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

#### **Break**

9:15 am-9:45 am

# Plenary Session 6: DNA Repair and PARP Inhibitors

9:45 am-11:15 am

Session Chair: Dyeison Antonow, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil

9:45-10:15	Targeting DNA repair in cancer therapy Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, MA
10:15-10:45	PARP trapping and Schlafen 11 to kill cancer cells Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD
10:45-11:15	Methods for defining DNA repair defects in human cancer Simon N. Powell, Memorial Sloan Kettering Cancer Center, New York, NY

#### Break

11:15 am-11:30 am





## Plenary Session 7: Hormone-Dependent Cancers and Steroid Receptors

11:30 am-1:00 pm

Session Chair: Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

11:30-12:00	Lessons for ER+ breast cancer from neoadjuvant endocrine therapy trials Matthew J. Ellis, Baylor College of Medicine, Houston, TX
12:00-12:30	Targeting DNA repair dysfunction in prostate cancer Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
12:30-1:00	Targeting DNA repair deficiencies in breast cancer Samuel Aparicio, BC Cancer Research Centre, Vancouver, BC, Canada

## Poster Session B / Lunch

1:00 pm-3:00 pm

# **Plenary Session 8: Oncogenes and Tumor Suppressors**

3:15 pm-4:45 pm

Session Chair: Roger Chammas, University of São Paulo, Sao Paulo, Brazil

3:15-3:45	Strategies to prevent and treat resistance to EGFR inhibitors in lung cancer Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
3:45-4:15	Tumor suppressor and tumor maintenance genes Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, NY
4:15-4:45	Long noncoding RNA-mediated RNA editing as a new mechanism of tumor suppressor gene inactivation Emmanuel Dias-Neto, A.C. Camargo Cancer Center, São Paulo, Brazil

#### **Break**

4:45 pm-5:00 pm

## **Plenary Session 9: Epigenetics**

5:00 pm-6:00 pm

Session Chair: Paulo M. Hoff, Centro de Oncologia, São Paulo, Brazil



5:00-5:30 The promise among the setbacks for epigenetic therapy in solid tumors

Nilofer S. Azad, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore,

MD

5:30-6:00 Defining cancer specific epigenomic signature associated with glioma progression

Houtan Noushmehr, University of São Paulo, Ribeirao Preto, São Paulo, Brazil

# **Closing Remarks**

6:00 pm-6:15 pm

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN Carlos Gil M. Ferreira, D'or Institute for Research and Education, Rio de Janeiro, Brazil